Protox Therapeutics Inc T.PRX

PRX 5-STAR RATING

[cabbieJBJ]

now at *****.  Others see a lot of value going forward.

Looks like we've leveled out at approx. $1.00 awaiting P2b NR.  Another pop at that time is likely.

Apropos the data, I believe it is practice is for the data for the company conducting the clinical to send the data to a third party for analysis, so PRX may not have had it for very long given the holidays.  That said, I strongly believe they know the direction of the results, if not the specifics.

Given the incidence of past failures of BPH therapies at P3, a financing by PRX to fund this phase may be needed to unlock sharholder value.  That means dilution...nlt 10 million shares imho.  The cost of P2b was about $25K per subject;  P3 will require about 3 -4 X more subjects, details pending a meeting with FDA on P3 success criteria.  If P2b is positive on the high end, with a continued excellent safety profile, P3 could be simpler and threfore cost less.  I put the probability of the PRX financing P3 at about 66%.

I put the probability of a co-development deal at about 33%.  We keep reading about the shallow pipeline of new drugs with the majors. 

I put the probability of an aquisition at <1%, but someone with bra$$ ball$ may want to step up.  The cancer drugs would be the key basis for interest.

Sorry for rambling or covering covered ground...just putting in time waiting for the NR.

[bioboy10]

Lot of ways to unlock shareholder value..I doubt that PRX could under take a much larger Phase 3 study, without help from Big Pharma.  Phase 3 takes a lot of time money and expertise.Going into partnership would be my perferred way. Lock in a partner for Phase 3 and also to move the cancer studies. A partnership in the 500,000 range would be perfectBut what do I know, Its a tough decision

[cabbieJBJ]

Bioboy: While I also would like to see your preferred option, I disagree that PRX needs big pharma for P3.  I expect that the results from P2a will be positive and consistent with earlier open label.  Based on that assessment, P3 likely will be an expansion of P2b...a larger sample size measuring the same result popints: prostate volume, urine flow, QoL and side effects/adverse

[hawkeye77]

This post has been removed in accordance with Community Policy

[cabbieJBJ]

fair point hawkeye.  We still need the NR and THE PLAN.  Very little volume today.  Still the low ball bid for 10 board lots @ .95...but he's accustomed to disappointment! :-) jb